A detailed history of China Universal Asset Management Co., Ltd. transactions in Immunity Bio, Inc. stock. As of the latest transaction made, China Universal Asset Management Co., Ltd. holds 133,966 shares of IBRX stock, worth $350,990. This represents 0.06% of its overall portfolio holdings.

Number of Shares
133,966
Previous 81,250 64.88%
Holding current value
$350,990
Previous $513,000 3.12%
% of portfolio
0.06%
Previous 0.07%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 25, 2024

BUY
$3.32 - $6.7 $175,017 - $353,197
52,716 Added 64.88%
133,966 $497,000
Q2 2024

Jul 19, 2024

SELL
$4.82 - $9.15 $226,882 - $430,699
-47,071 Reduced 36.68%
81,250 $513,000
Q1 2024

Apr 29, 2024

BUY
$3.23 - $6.17 $165,007 - $315,200
51,086 Added 66.14%
128,321 $689,000
Q4 2023

May 21, 2024

SELL
$1.25 - $5.21 $63,857 - $266,158
-51,086 Reduced 39.81%
77,235 $387,000
Q4 2023

Jan 23, 2024

BUY
$1.25 - $5.21 $81,916 - $341,426
65,533 Added 560.02%
77,235 $388,000
Q3 2023

May 21, 2024

BUY
$1.29 - $3.1 $7,723 - $18,559
5,987 Added 104.76%
11,702 $19,000
Q3 2023

Oct 30, 2023

BUY
$1.29 - $3.1 $7,723 - $18,559
5,987 Added 104.76%
11,702 $20,000
Q2 2023

May 21, 2024

BUY
$1.53 - $6.41 $153 - $641
100 Added 1.78%
5,715 $15,000
Q2 2023

Jul 27, 2023

BUY
$1.53 - $6.41 $153 - $641
100 Added 1.78%
5,715 $16,000
Q1 2023

May 21, 2024

BUY
$1.35 - $4.78 $2,089 - $7,399
1,548 Added 38.06%
5,615 $10,000
Q1 2023

Apr 27, 2023

BUY
$1.35 - $4.78 $2,089 - $7,399
1,548 Added 38.06%
5,615 $10,000
Q4 2022

May 21, 2024

SELL
$4.35 - $6.77 $540,504 - $841,199
-124,254 Reduced 96.83%
4,067 $20,000
Q4 2022

Jan 31, 2023

BUY
$4.35 - $6.77 $1,383 - $2,152
318 Added 8.48%
4,067 $21,000
Q3 2022

Oct 21, 2022

BUY
$3.65 - $6.43 $13,683 - $24,106
3,749 New
3,749 $19,000

Others Institutions Holding IBRX

About ImmunityBio, Inc.


  • Ticker IBRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 400,304,000
  • Market Cap $1.05B
  • Description
  • ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The com...
More about IBRX
Track This Portfolio

Track China Universal Asset Management Co., Ltd. Portfolio

Follow China Universal Asset Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of China Universal Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on China Universal Asset Management Co., Ltd. with notifications on news.